106 related articles for article (PubMed ID: 12764435)
1. Anti-human immunodeficiency virus-1 antibody titers in injection drug users compared to sexually infected individuals.
Bongertz V; Ouverney EP; Teixeira SL; Silva-de-Jesus C; Hacker MA; Morgado MG; Bastos FI
Mem Inst Oswaldo Cruz; 2003 Mar; 98(2):209-12. PubMed ID: 12764435
[TBL] [Abstract][Full Text] [Related]
2. HIV-1 binding and neutralizing antibodies of injecting drug users.
Ouverney EP; Teixeira SL; Silva-de-Jesus C; Hacker MA; Morgado MG; Bastos FI; Bongertz V
Braz J Med Biol Res; 2005 Sep; 38(9):1313-20. PubMed ID: 16138213
[TBL] [Abstract][Full Text] [Related]
3. Antibody responses to HIV-1 envelope and gag epitopes in HIV-1 seroconverters with rapid versus slow disease progression.
Zwart G; van der Hoek L; Valk M; Cornelissen MT; Baan E; Dekker J; Koot M; Kuiken CL; Goudsmit J
Virology; 1994 Jun; 201(2):285-93. PubMed ID: 7514319
[TBL] [Abstract][Full Text] [Related]
4. Search for epitope-specific antibody responses to the human immunodeficiency virus (HIV-1) envelope glycoproteins signifying resistance to disease development.
Neurath AR; Strick N; Taylor P; Rubinstein P; Stevens CE
AIDS Res Hum Retroviruses; 1990 Oct; 6(10):1183-92. PubMed ID: 1701315
[TBL] [Abstract][Full Text] [Related]
5. Anti-HIV-1 seroreactivity and HIV transmission route[R1]. The HEC/FIOCRUZ AIDS Clinical Research Group.
Bongertz V; Guimarães ML; Soares-da-Costa MF; Veloso VG; Bastos FI; Szwarcwald CL; Derrico M; Telles PR; Pilloto JH; João Filho EC; Morgado MG
J Clin Virol; 1999 Jan; 12(1):27-36. PubMed ID: 10073411
[TBL] [Abstract][Full Text] [Related]
6. Maternal antibodies to HIV-1 envelope domains: No correlation with HIV-1 vertical transmission in patients from Argentina.
Calarota SA; Libonatti OV
Scand J Immunol; 2000 Sep; 52(3):292-7. PubMed ID: 10972906
[TBL] [Abstract][Full Text] [Related]
7. Peptide serology for analysis of the inter- and intra-individual variation in the HIV-1 V3 domain.
Jansson M; Wahren B; Albert J; Scarlatti G; Franzén L; Kataaha PK; Katabira E; Mubiro F; Wigzell H; Rossi P
AIDS; 1994 Apr; 8(4):413-21. PubMed ID: 8011244
[TBL] [Abstract][Full Text] [Related]
8. B cell epitope mapping of human immunodeficiency virus envelope glycoproteins with long (19- to 36-residue) synthetic peptides.
Neurath AR; Strick N; Lee ES
J Gen Virol; 1990 Jan; 71 ( Pt 1)():85-95. PubMed ID: 1689372
[TBL] [Abstract][Full Text] [Related]
9. Evidence of no change in V3 loop antibody recognition pattern in HIV type 1-infected Ethiopians between 1988 and 1993.
Sherefa K; Sällberg M; Sönnerborg A
AIDS Res Hum Retroviruses; 1994 Nov; 10(11):1551-6. PubMed ID: 7534097
[TBL] [Abstract][Full Text] [Related]
10. Human immunodeficiency virus type 1 neutralization by plasma from B or F genotype infected individuals.
Bongertz V; Teixeira SL; Grinztejn B; Pilotto JH; Veloso VG; Morgado MG; Bastos FI; Ouverney EP
Mem Inst Oswaldo Cruz; 2005 Feb; 100(1):85-9. PubMed ID: 15867970
[TBL] [Abstract][Full Text] [Related]
11. High prevalence of antibodies to the gp120 V3 region principal neutralizing determinant of HIV-1MN in sera from Africa and the Americas.
Carrow EW; Vujcic LK; Glass WL; Seamon KB; Rastogi SC; Hendry RM; Boulos R; Nzila N; Quinnan GV
AIDS Res Hum Retroviruses; 1991 Oct; 7(10):831-8. PubMed ID: 1720630
[TBL] [Abstract][Full Text] [Related]
12. HIV type 1 subtype E-infected patients with broadened, dual (B/E) V3 loop serology have increased cross-neutralizing antibodies.
Polonis VR; De Souza MS; Chanbancherd P; Chantakulkij S; Jugsudee A; Loomis-Price LD; Vancott TC; Garner R; Markowitz LE; Brown AE; Birx DL
AIDS Res Hum Retroviruses; 2001 Jan; 17(1):69-79. PubMed ID: 11177385
[TBL] [Abstract][Full Text] [Related]
13. Relative reactivity of the V3 loop PND of HIV-1 subtypes A, B, C, D, and F with sera from selected Ugandan localities.
Riley JP; Pestano GA; Hosford K; Francis C; Xie JM; Mugyenyi P; Kataaha P; Katongole-Mbidde E; Anokbonggo WW; Guyden J
Arch Virol; 1995; 140(8):1393-404. PubMed ID: 7544970
[TBL] [Abstract][Full Text] [Related]
14. Reactions of Ugandan antisera with peptides encoded by V3 loop epitopes of human immunodeficiency virus type 1.
Smith JD; Bruce CB; Featherstone AS; Downing RG; Biryahawaho B; Clegg JC; Carswell JW; Oram JD
AIDS Res Hum Retroviruses; 1994 May; 10(5):577-83. PubMed ID: 7522494
[TBL] [Abstract][Full Text] [Related]
15. Antigenic activity of three chimeric synthetic peptides of the transmembrane (gp41) and the envelope (gp120) glycoproteins of HIV-1 virus.
Marin MH; Peña LP; Tanty CR; Higginson Clarke D; Arenas MA; Noguerol KR; León CS
Prep Biochem Biotechnol; 2004 Aug; 34(3):227-37. PubMed ID: 15461139
[TBL] [Abstract][Full Text] [Related]
16. Maternal antibodies to gp120 V3 sequence do not correlate with protection against vertical transmission of human immunodeficiency virus.
Robertson CA; Mok JY; Froebel KS; Simmonds P; Burns SM; Marsden HS; Graham S
J Infect Dis; 1992 Oct; 166(4):704-9. PubMed ID: 1527406
[TBL] [Abstract][Full Text] [Related]
17. Relative reactivity of HIV-1 polyclonal plasma antibodies directed to V3 and MPER regions suggests immunodominance of V3 over MPER and dependence of high anti-V3 antibody titers on virus persistence.
Andrabi R; Choudhary AK; Bala M; Kalra R; Prakash SS; Pandey RM; Luthra K
Arch Virol; 2011 Oct; 156(10):1787-94. PubMed ID: 21735212
[TBL] [Abstract][Full Text] [Related]
18. Vertical transmission of human immunodeficiency virus (HIV) infection. Reactivity of maternal sera with glycoprotein 120 and 41 peptides from HIV type 1.
Ugen KE; Goedert JJ; Boyer J; Refaeli Y; Frank I; Williams WV; Willoughby A; Landesman S; Mendez H; Rubinstein A
J Clin Invest; 1992 Jun; 89(6):1923-30. PubMed ID: 1601999
[TBL] [Abstract][Full Text] [Related]
19. Patterns of immunoglobulin G subclass reactivity to HIV-1 envelope peptides in children born to HIV-1-infected mothers.
Jansson M; Wahren B; Scarlatti G; Principi N; Lombardi V; Livadiotti S; Elia L; Plebani A; Wigzell H; Rossi P
AIDS; 1992 Apr; 6(4):365-71. PubMed ID: 1616634
[TBL] [Abstract][Full Text] [Related]
20. Vertical transmission of human immunodeficiency virus type 1: seroreactivity by maternal antibodies to the carboxy region of the gp41 envelope glycoprotein.
Ugen KE; Srikantan V; Goedert JJ; Nelson RP; Williams WV; Weiner DB
J Infect Dis; 1997 Jan; 175(1):63-9. PubMed ID: 8985197
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
